215 First Street
About Neon Therapeutics
NEON Therapeutics is focused on unlocking the full potential of the immune system to recognize and attack cancer.
Founders: James Allison, Ed Fritsch, Nir Hacohen, and Eric Lander
CEO: Hugh O'Dowd
CBO: Robert Ang
CTO: ED Fritsch
CMO: Barbara Weber
CFO: Daniella Beckman
Please click here for Neon job opportunities.
51 articles with Neon Therapeutics
BioNTech indicates the acquisition will add production capacity in support of U.S. clinical trials.
BioNTech will open a state-of-the-art manufacturing facility in Singapore to support a global supply of mRNA-based vaccines and therapeutics.
BioNTech announced the closing of the Neon Therapeutics, Inc. acquisition through an all-stock transaction.
Neon Therapeutics Announces Acceptance of European Clinical Trial Authorization Application for NEO-PTC-01Phase 1 Clinical Trial of Personal Neoantigen-Targeted T Cell Therapy Expected to Initiate in Third Quarter 2020
Neon Therapeutics, Inc. announced the acceptance of its Clinical Trial Authorization from the Dutch Health Authority for its personal neoantigen-targeted T cell therapy candidate, NEO-PTC-01.
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Neon Therapeutics, Inc. ("NTGN" or the "Company") (NASDAQ: NTGN) in connection with the proposed acquisition of the Company by BioNTech ("BNTX") (NASDAQ: BNTX).
Neon Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
Neon Therapeutics, Inc. (Nasdaq: NTGN) today reported financial results for the fourth quarter and full-year ended December 31, 2019 and provided a business update.
“This acquisition fits with our strategy to expand our capabilities and build our presence in the U.S. and further strengthens our immunotherapy pipeline,” said Ugur Sahin, co-founder and chief executive officer of BioNTech.
Neon Therapeutics Submits European Clinical Trial Authorization Application for Personal Neoantigen-Targeted T Cell Therapy NEO-PTC-01Study of NEO-PTC-01 in metastatic melanoma patients expected to initiate in first half of 2020
Neon Therapeutics, Inc. (Nasdaq: NTGN) today announced that it has filed a Clinical Trial Authorization (CTA) with the Dutch Health Authority for the evaluation of NEO-PTC-01 in patients with metastatic melanoma who are refractory to checkpoint inhibitors.
12/13/2019Pharma and biotech companies strengthen their leadership teams and boards with this week's hires.
According to PhRMA, there are 264 vaccines in development to prevent and treat diseases. These include infectious diseases (137), cancer (101), allergies (10), autoimmune disease (8) and Alzheimer’s disease (4).
Neon Therapeutics, Inc. (Nasdaq: NTGN) today announced its new strategic focus on the development of its novel neoantigen-based T cell programs, in conjunction with a corporate restructuring. Neon will focus its efforts on the advancement of both personal and precision neoantigen-targeted T cell therapy candidates.
Neon Therapeutics Reports Third Quarter 2019 Financial Results and Recent HighlightsRecent Progress Achieved Across RECON® Bioinformatics Platform and Lead Neoantigen-Targeted Immunotherapy Programs
Neon Therapeutics, Inc., a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, reported financial results for the third quarter ended September 30, 2019 and provided a business update.
Neon Therapeutics Announces Updated Data Presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today presented updated data at the Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting in National Harbor, MD.
7/22/2019Here's a look at the top clinical trial news from last week, with updates from Neon, GSK, Biohaven, and more.
In all three cancer types, data showed prolonged and consistent improvements in progression-free survival (PFS) that is similar to that seen with checkpoint inhibitor monotherapy.
We thought it would be insightful to look back at our previous lists to see where some of those companies are today. Here’s a look at the top 3 companies from the Top 20 Life Science Startups to Watch in the U.S. from 2017.
Every year, BioSpace analyzes the biotech industry, looking for the hot new biotech startups to watch. Here’s a look at the top 3 companies from the Top 20 Life Science Startups to Watch in the U.S. from 2016.
Although the size of the IPO is one aspect of determining the success of a company’s public launch, it’s not the only metric. How the stock does in the ensuing months is a very important consideration.
Most of the IPOs that occurred in the Bay State have been well-documented by BioSpace. But, with a new calendar year upon us, it’s a good idea to look back at a banner year of capitalization that may not repeat when January rolls around. With the turn of the year only days away, BioSpace takes a ...
Natera and Neon Therapeutics Announce Clinical Trial Collaboration to Assess Treatment Response to Personal Cancer Vaccine
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, and Neon Therapeutics, Inc. (NASDAQ: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced a research collaboration using Natera's Signatera™ (RUO) circulating tumor DNA (ctDNA) assay as a biomarker to assess treatment response to NEO-PV-01 in Neon Therapeutics' NT-002 clinical trial.